NCT05130892View on ClinicalTrials.gov

Effect of Inflammasome Inhibitor on hsCRP in Patients After PCI

PHASE4CompletedINTERVENTIONAL
Enrollment

132

Participants

Timeline

Start Date

November 15, 2021

Primary Completion Date

February 1, 2023

Study Completion Date

February 1, 2023

Conditions
NLRP3hsCRPPercutaneous Coronary Intervention
Interventions
DRUG

Colchicine

1 tablet (0.5mg) / time, once a day

DRUG

Tranilast

1 capsule (0.1g) / time, 3 times a day

DRUG

Oridonin

2 tablets (0.5g) / time, 3 times a day;

Trial Locations (2)

430022

Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan

Unknown

Wuhan Union Hospital, Wuhan

All Listed Sponsors
lead

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

OTHER

NCT05130892 - Effect of Inflammasome Inhibitor on hsCRP in Patients After PCI | Biotech Hunter | Biotech Hunter